Deployable Evidence vs Research Still Needed.
The single most common objection to acting on the gender health gap is we need more research. Some of it is fair. Much of it is not. This essay draws the line, carefully.
The objection, and why it functions as a delay
In any regulatory, funder, or payer conversation about women's health, the recurring sentence is that the evidence is emerging, the signals are suggestive, and more research is needed before action is warranted. This sentence is deployed across findings that differ wildly in their evidentiary status. Some of them genuinely warrant that caveat. Others are supported by three decades of replicated, peer-reviewed work and a clear mechanism, and attaching more-research-is-needed to them is not epistemic humility but inertia.
The absence of a shared criteria for deployability allows the objection to move fluidly between categories. A finding that is actually deployable gets treated as if it required further research; a finding that genuinely does need further research gets treated as if it already failed to survive scrutiny. The conversation stalls in both directions simultaneously.
Four criteria for deployability
A finding is deployable when all four of the following conditions are met. If any one fails, the finding moves to research-still-needed, or to a smaller scoped pilot.
Six findings that meet all four criteria
Each item below passes all four tests. They are deployable now. The phrase "more research is needed" applied to them is, politely, a placeholder for "we have not scheduled the action."
The same findings, plotted on the two axes that matter
Mechanistic certainty sits on the horizontal axis. Action readiness — whether the clinical, billing, or regulatory lever already exists — sits on the vertical. A finding in the top-right quadrant is deployable. A finding in the bottom-left is genuinely research-frontier. The middle two quadrants are pilots and stopped programs respectively. Points are positioned by the authors' calibrated reading of the underlying literature and are illustrative rather than meta-analytic.
Positioning reflects the authors' calibrated reading of each finding's evidentiary base against the four deployability criteria. The two clusters are separated by a clear diagonal band, not because the underlying science is neatly bimodal, but because the four criteria above happen to move together: a finding with a replicated effect and traceable mechanism tends to already have a lever and a defined population, because those attributes accrete during the same decades of work.
The cost of the distinction: how long the deployable evidence has been waiting
Each deploy-column finding has an evidence-publication date and a current implementation rate. The gap between the two is not a measure of epistemic caution; it is a measure of institutional lag. The horizon bars below encode that gap on a calendar from the year of first major meta-analysis (or equivalent consolidation) to 2026, with the darker overlay showing the fraction of the at-risk population currently receiving the indicated action.
The lightest band encodes the span of years during which each finding has been consolidated in peer-reviewed literature; the solid overlay encodes the fraction of the target population currently receiving the indicated action. Implementation-rate figures are taken from the respective specialty surveillance literatures and rounded for display; the directional point — long known, barely deployed — is robust to reasonable variation in the exact percentage.
Why the distinction matters operationally
A regulator, a funder, or a payer who internalises the two-column ledger above can move immediately. The deploy column converts directly into policy instruments: CMS bundled-payment extension, FDA pre-specification guidance, commercial-payer clinical-pathway updates, CPT code additions, reimbursement-protocol modifications. None of these require waiting on the research column. None of them are contingent on the research column.
The research column, separately, carries its own funding and design implications. It should be resourced as a distinct portfolio, not as a justification for inaction on the deploy column. The NIH Sex as a Biological Variable policy, in its 2016 form, was precisely this kind of research-portfolio instrument. Its enforcement gap is documented (IQVIA 2025) but the enforcement-gap conversation is separate from the deploy-column conversation.
When the two columns are collapsed, the result is the status quo: every finding is treated as pre-deployable, every action is postponed, and the cumulative national cost of the gender health gap continues to be paid from the downstream clinical and disability budgets while the upstream action remains unscheduled.
One specific request to funders, regulators, and health-system leads
Every internal memo, guideline draft, and policy brief that references women's health research should, as a formatting convention, list findings under the two-column format used here. The convention forces the question what action does this imply? on every finding at the moment of citation. It is a small editorial change. It converts the deploy column into an operational queue and the research column into a funded program, without allowing the two to substitute for each other.
This essay is short on purpose. The framework is the deliverable. The six deploy-column items are not controversial within their specialty literatures. They are, institutionally, still waiting to be scheduled.
Related reading: Pathway Failure Is Correctable for the thesis; Pricing the Pathway for the actuarial-profession deploy list; Pregnancy Is a Cardiovascular Stress Test for a fully-worked single-example deploy case.